Hyperstable Liposomes for Sustained Anti-Mitotic Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mitosis-regulating enzyme-targeting drugs, such as Polo-like Kinases and Aurora kinases, face limited efficacy due to the low proportion of tumor cells in division, necessitating sustained bioavailability to effectively target cancer cells, while existing liposomal drug delivery systems face challenges in maintaining high tumoral concentrations and stability.
Innovation Solution
Development of hyperstable liposomes encapsulating anti-mitotic drugs like BI 2536, with a specific lipid composition and anion ratio, which slow the release of the drug to maintain prolonged bioavailability and increase the fraction of targetable cancer cells, using a membrane comprising DSPE-PEG2000, HEPC, and Chol, and anions like citrate and phosphate to control drug release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional liposomal drug delivery systems are used to deliver mitosis-inhibiting agents, then the drugs can be delivered to tumor cells, but the drug release rate is too fast to sustain bioavailability long enough to target sufficient dividing cancer cells
Solution Approach 1:
The patent changes the physical-chemical parameters of the liposome system by incorporating specific anions (phosphate, citrate, acetate) in optimized ratios within the liposome interior. This creates a controlled release mechanism where the anion composition regulates drug diffusion rate, extending bioavailability from hours to days and enabling sustained targeting of mitotic cells.
Solution Approach 2:
The invention uses a composite liposome structure combining phospholipids, cholesterol, PEGylated lipids, and specific anions in defined ratios. This composite formulation creates a hyperstable liposome with controlled permeability and sustained drug release characteristics that conventional single-component liposomes cannot achieve.
2Reliability
If mitosis-regulating enzyme-targeting drugs are administered frequently to maintain sustained bioavailability, then more dividing cancer cells can be targeted, but treatment complexity and patient burden increase
Solution Approach 1:
The hyperstable liposomes provide continuous drug release over an extended period (sustained bioavailability), ensuring that therapeutic concentrations are maintained continuously in the tumor microenvironment. This eliminates the need for frequent dosing intervals while maintaining reliable targeting of all dividing cancer cells that occur during the extended release period.
3Productivity
If conventional liposomes are used with mitosis-inhibiting agents, then some tumor reduction can be achieved, but complete responses are rare and toxicity including neuropathy occurs
Solution Approach 1:
The hyperstable liposome acts as an intermediary delivery vehicle that protects the mitosis-inhibiting agent during circulation and controls its release at the target site. This mediated delivery improves tumor reduction efficacy while the controlled release profile reduces systemic toxicity and neuropathy by maintaining lower peak concentrations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hyperstable liposomes achieve prolonged tumor reduction and increased cancer cell killing, with a single dose showing 20% complete responses and two doses resulting in 75% response rate, while maintaining low toxicity and avoiding neuropathy, thus enhancing the clinical utility of mitosis-inhibiting agents.
Implementation Method 1
Liposomes are known to exploit fenestrations in tumor endothelium to access and persist in tumor tissues. This phenomenon, called the Enhanced Permeability and Retention (EPR) effect
Implementation Method 2
small molecules, including drugs, may be 'remotely loaded' into liposomes by creating a physicochemical differential between the internal and external environment of the liposome. If the drug is a weak base, one way to create this differential is to encapsulate buffering anions in the liposome interior which create a low pH relative to the exterior.
Implementation Method 3
a hyperstable liposome comprising an inner milieu separated from an external environment by a membrane, the inner milieu comprising an anti-mitotic drug, two anions and one or more cations entrapped in the inner milieu
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Hyperstable liposome comprising an anti-mitotic agent, one or more anions and one or more cations entrapped in the inner milieu, wherein the entrapped anti-mitotic drug is released at a slow rate that is less than 0.6% in 12 hours or less than 5% in 8 hours when the liposomes are suspended in 600mM sucrose. These liposomes are useful in the treatment of cancer. In particular, HEPC:Chol:DSPE-PEG2000 (50:45:5) liposomes comprising BI 2536 and citrate:phosphate in a ratio of 1 :3.